Tolbutamide pharmacogenetics and the UGDP controversy.
We analyzed the relationship between the pharmacogenetics of tolbutamide metabolism and the controversial University Group Diabetes Program (UGDP) study. Before the institution of that study, the extent of genetic control over the variation in the rate of tolbutamide metabolism was unknown, and all subjects included in the tolbutamide treatment group were given 1,500 mg/day of tolbutamide in a fixed dosage. We addressed the hypothesis that high accrued blood levels of tolbutamide in genetically predisposed slow inactivators might have contributed to the toxic effects reported by the UGDP study. This proposal is based on recent findings from population, twin, and family studies that tolbutamide metabolism is under monogenic control, with nearly one fourth of the population classified as slow inactivators.
D000483:Alleles; D044383:Black People; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000401:mortality; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D005796:Genes; D006801:Humans; D008297:Male; D008722:Methods; D009203:Myocardial Infarction / Q000453:epidemiology / Q000401:mortality; D010597:Pharmacogenetics; D012306:Risk; D012737:Sex Factors; D014044:Tolbutamide / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D044465:White People
D014044:Tolbutamide